BÜHLMANN Laboratories AG Receives FDA Clearance For Its fCAL® Turbo Automated, Random Access Calprotectin Test

BÜHLMANN Laboratories AG Receives FDA Clearance for Its fCAL® turbo
Automated, Random Access Calprotectin Test
BÜHLMANN fCAL® turbo, an in vitro diagnostic assay intended for the quantitation of calprotectin
in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is
now commercially available in the US.
Amherst, NH, June 27, 2019 --(PR.com)-- BÜHLMANN Laboratories AG is proud to announce it
received United States Food and Drug Administration (FDA) 510(k) clearance of its BÜHLMANN
fCAL® turbo. This turbidimetric test was successfully launched all over the world and is now available
on the U.S. market. The BÜHLMANN fCAL® turbo is an in vitro diagnostic assay intended for the
quantitative measurement of fecal calprotectin (fCAL), a neutrophilic protein that is a marker of intestinal
mucosal inflammation, in human stool. The BÜHLMANN fCAL® turbo aids in the diagnosis of
inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids
in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory
and clinical findings. Utilizing calprotectin for diagnostic testing demands the test be accurate and
reproducible over long periods of time which is one of the key characteristics of BÜHLMANN fCAL®
turbo.
The use of a non-invasive inflammation bio-marker such as calprotectin is crucial with the increasing
prevalence of gastrointestinal disease and the challenges of traditional treatment pathways. The 2018
clinical guidelines of the American College of Gastroenterology (ACG) strongly recommends fCAL as
helpful test that should be considered as an aid to differentiate the presence of IBD from IBS. As a result,
major health insurance companies have started covering calprotectin testing (CPT: 83993).
Due to the quality performance and high capacity of BÜHLMANN fCAL® turbo, this assay can be
applied economically in low/mid volume laboratories as well as in very high volume reference labs.
Testing turnaround time can be reduced significantly not only compared to the existing ELISA methods
but also to other automated, random access calprotectin assays. BÜHLMANN fCAL® turbo is a real
milestone for efficient handling of increasing workloads in the laboratory being the highest throughput
calprotectin assay with the fastest time-to-first-result in the U.S. market.
Doug Olson, CEO of BUHLMANN Diagnostics Corp commented, “We are very pleased to launch this
robust, high quality assay to assist physicians in evaluating patients in a timely manner and to help
laboratories across North America to meet the increasing demand for calprotectin testing. This test
provides a high throughput option to our FDA cleared BÜHLMANN fCAL® ELISA, providing
flexibility in testing options. Most importantly, this assay portfolio offers consistency - no matter which
assay you choose, results are reliable, accurate, and consistent across the platforms.”
In a multi-site clinical study, BÜHLMANN fCAL® turbo demonstrated excellent precision and
reproducibility, while confirming that this test is a valuable diagnostic aid in the diagnosis of IBD and in
the discrimination between IBD and IBS.
Page 1/3
PR.com Press Release Distribution Terms of Use
Visit www.buhlmannlabs.com to learn more about this assay, and overall performance.
About BÜHLMANN Laboratories AG

Founded in 1976, BÜHLMANN Laboratories AG has continued to focus on growing a product portfolio
of in vitro diagnostics and research markets. BÜHLMANN is known for outstanding product quality,
providing excellent after-sales services, and delivering remarkable scientific innovations. BÜHLMANN
offers the broadest range of calprotectin products as well as a selection of unique, high-quality assays
such as the BÜHLMANN Flow CAST® product group for Basophil Activation Testing, the
BÜHLMANN GanglioCombi™ products for neuroimmunology, and a variety of Melatonin Assays.
About BUHLMANN Diagnostics Corp (BDC)

BUHLMANN Diagnostics Corp (BDC) is the North American affiliate of BÜHLMANN Laboratories
AG, the worldwide provider of ELISA kits, RIA kits, lateral flow and flow cytometry assays. Located in
Southern New Hampshire, BDC has a highly experienced team who represent a breadth of experience in
serving both clinical and basic science research laboratories.
About BÜHLMANN Calprotectin Product Line

The calprotectin portfolio consists of the BÜHLMANN fCAL® ELISA (FDA 510(k) cleared),
BÜHLMANN fCAL® turbo (FDA 510(k) cleared) for testing on most clinical chemistry analyzers (RUO
in the US), Quantum Blue® fCAL Rapid Test (RUO in the US), and IBDoc®, the first and only Health
Canada Licensed home-testing application for fecal calprotectin in IBD patients (IBDoc® not available
for sale in the US).
Page 2/3
Contact Information:
BUHLMANN Diagnostics Corp
Stacy Smith
844-300-9799
Contact via Email
www.buhlmannlabs.com
[email protected]
Online Version of Press Release:

You can read the online version of this press release at: https://www.pr.com/press-release/788419
News Image:
Page 3/3

BÜHLMANN Laboratories AG Receives FDA Clearance For Its fCAL® Turbo Automated, Random Access Calprotectin Test

Uploaded by

Copyright:

BÜHLMANN Laboratories AG Receives FDA Clearance For Its fCAL® Turbo Automated, Random Access Calprotectin Test

Uploaded by

Document Information

Original Title

Copyright

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

BÜHLMANN Laboratories AG Receives FDA Clearance For Its fCAL® Turbo Automated, Random Access Calprotectin Test

Uploaded by

Copyright:

BÜHLMANN Laboratories AG Receives FDA Clearance for Its fCAL® turbo

Automated, Random Access Calprotectin Test

About BÜHLMANN Laboratories AG

About BUHLMANN Diagnostics Corp (BDC)

About BÜHLMANN Calprotectin Product Line

Online Version of Press Release:

You might also like